25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ABBV (Abbvie) Stock Analysis
Buy, Hold or Sell?

Let's analyze Abbvie together

I guess you are interested in AbbVie Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Abbvie’s Financial Insights
  • 📈 Technical Analysis (TA) – Abbvie’s Price Targets

I'm going to help you getting a better view of AbbVie Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AbbVie Inc

I send you an email if I find something interesting about AbbVie Inc.

1. Quick Overview

1.1. Quick analysis of Abbvie (30 sec.)










1.2. What can you expect buying and holding a share of Abbvie? (30 sec.)

How much money do you get?

How much money do you get?
$6.31
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$0.83
Expected worth in 1 year
$-2.89
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$2.59
Return On Investment
1.4%

For what price can you sell your share?

Current Price per Share
$187.63
Expected price per share
$176.57 - $199.46
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Abbvie (5 min.)




Live pricePrice per Share (EOD)
$187.63
Intrinsic Value Per Share
$-23.22 - $98.13
Total Value Per Share
$-22.39 - $98.95

2.2. Growth of Abbvie (5 min.)




Is Abbvie growing?

Current yearPrevious yearGrowGrow %
How rich?$1.4b$10.8b-$6.4b-145.3%

How much money is Abbvie making?

Current yearPrevious yearGrowGrow %
Making money$1b$1.4b-$449.5m-42.9%
Net Profit Margin7.4%11.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Abbvie (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Abbvie?

Welcome investor! Abbvie's management wants to use your money to grow the business. In return you get a share of Abbvie.

First you should know what it really means to hold a share of Abbvie. And how you can make/lose money.

Speculation

The Price per Share of Abbvie is $187.63. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abbvie.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abbvie, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.83. Based on the TTM, the Book Value Change Per Share is $-0.93 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.74 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $1.58 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abbvie.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.730.4%0.590.3%0.840.4%0.830.4%1.000.5%0.950.5%
Usd Book Value Change Per Share-1.07-0.6%-0.93-0.5%-0.74-0.4%-0.70-0.4%0.250.1%0.000.0%
Usd Dividend Per Share1.650.9%1.580.8%1.500.8%1.500.8%1.400.7%1.040.6%
Usd Total Gains Per Share0.580.3%0.650.3%0.760.4%0.810.4%1.650.9%1.040.6%
Usd Price Per Share209.52-189.06-155.22-165.45-145.23-110.53-
Price to Earnings Ratio72.18--849.15-52.32--231.13--68.27--5.65-
Price-to-Total Gains Ratio362.25-2,078.49-333.30-822.60-455.69-207.18-
Price to Book Ratio253.95-112.44-26.70-52.32-37.08-20.71-
Price-to-Total Gains Ratio362.25-2,078.49-333.30-822.60-455.69-207.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share187.63
Number of shares5
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.581.40
Usd Book Value Change Per Share-0.930.25
Usd Total Gains Per Share0.651.65
Gains per Quarter (5 shares)3.248.26
Gains per Year (5 shares)12.9733.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
132-19328523
263-3716561056
395-5629841589
4126-744211220122
5158-935514025155
6189-1116816830188
7221-1308119635221
8252-1499422440254
9284-16710725245287
10315-18612028050320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%37.03.00.092.5%54.04.00.093.1%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%20.020.00.050.0%28.027.03.048.3%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%49.00.09.084.5%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%32.08.00.080.0%43.012.03.074.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AbbVie Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.072-0.928-13%-0.738-31%-0.696-35%0.251-527%0.001-94358%
Book Value Per Share--0.8252.500-67%6.134-87%5.754-86%6.684-88%3.442-76%
Current Ratio--0.7600.718+6%0.915-17%0.852-11%0.862-12%1.214-37%
Debt To Asset Ratio--0.9890.968+2%0.921+7%0.927+7%0.917+8%0.955+4%
Debt To Equity Ratio--94.86144.301+114%12.342+669%21.613+339%16.743+467%11.835+702%
Dividend Per Share--1.6511.577+5%1.503+10%1.504+10%1.402+18%1.041+59%
Enterprise Value--241742440000.000208058505000.000+16%160325307500.000+51%174627005833.333+38%136335887100.000+77%108426874350.000+123%
Eps--0.7260.592+23%0.844-14%0.834-13%0.997-27%0.951-24%
Ev To Ebitda Ratio--16.19029.277-45%6.907+134%13.879+17%9.467+71%7.872+106%
Ev To Sales Ratio--4.5293.650+24%2.979+52%3.133+45%2.462+84%2.603+74%
Free Cash Flow Per Share--0.7902.170-64%3.089-74%2.856-72%2.835-72%2.137-63%
Free Cash Flow To Equity Per Share--0.080-0.269+435%3.058-97%0.906-91%0.678-88%1.046-92%
Gross Profit Margin--1.0001.0000%0.331+202%0.710+41%-1.700+270%-0.777+178%
Intrinsic Value_10Y_max--98.128----------
Intrinsic Value_10Y_min---23.217----------
Intrinsic Value_1Y_max--11.211----------
Intrinsic Value_1Y_min--6.743----------
Intrinsic Value_3Y_max--32.633----------
Intrinsic Value_3Y_min--12.524----------
Intrinsic Value_5Y_max--52.791----------
Intrinsic Value_5Y_min--9.784----------
Market Cap331429632000.000-12%371269440000.000335007005000.000+11%275015557500.000+35%293403589166.667+27%257677737100.000+44%195813249350.000+90%
Net Profit Margin--0.0960.074+30%0.111-13%0.104-8%0.126-23%0.173-44%
Operating Margin--0.1270.142-11%0.284-55%0.262-51%0.297-57%0.343-63%
Operating Ratio--0.7200.800-10%0.732-2%0.746-3%0.727-1%0.694+4%
Pb Ratio227.415-12%253.946112.444+126%26.700+851%52.322+385%37.082+585%20.710+1126%
Pe Ratio64.635-12%72.175-849.150+1277%52.325+38%-231.125+420%-68.268+195%-5.648+108%
Price Per Share187.630-12%209.520189.055+11%155.215+35%165.453+27%145.230+44%110.531+90%
Price To Free Cash Flow Ratio59.371-12%66.29833.049+101%13.691+384%19.711+236%16.169+310%15.137+338%
Price To Total Gains Ratio324.404-12%362.2502078.491-83%333.295+9%822.597-56%455.690-21%207.181+75%
Quick Ratio--0.4850.4850%0.674-28%0.612-21%0.620-22%0.957-49%
Return On Assets--0.0090.007+27%0.011-13%0.011-11%0.012-24%0.018-48%
Return On Equity--0.9060.340+166%0.139+553%0.199+355%0.179+406%0.182+397%
Total Gains Per Share--0.5780.649-11%0.765-24%0.808-28%1.653-65%1.042-45%
Usd Book Value--1462000000.0004429500000.000-67%10867750000.000-87%10207833333.333-86%11863300000.000-88%6109075000.000-76%
Usd Book Value Change Per Share---1.072-0.928-13%-0.738-31%-0.696-35%0.251-527%0.001-94358%
Usd Book Value Per Share--0.8252.500-67%6.134-87%5.754-86%6.684-88%3.442-76%
Usd Dividend Per Share--1.6511.577+5%1.503+10%1.504+10%1.402+18%1.041+59%
Usd Enterprise Value--241742440000.000208058505000.000+16%160325307500.000+51%174627005833.333+38%136335887100.000+77%108426874350.000+123%
Usd Eps--0.7260.592+23%0.844-14%0.834-13%0.997-27%0.951-24%
Usd Free Cash Flow--1400000000.0003846250000.000-64%5472750000.000-74%5066333333.333-72%5031600000.000-72%3785975000.000-63%
Usd Free Cash Flow Per Share--0.7902.170-64%3.089-74%2.856-72%2.835-72%2.137-63%
Usd Free Cash Flow To Equity Per Share--0.080-0.269+435%3.058-97%0.906-91%0.678-88%1.046-92%
Usd Market Cap331429632000.000-12%371269440000.000335007005000.000+11%275015557500.000+35%293403589166.667+27%257677737100.000+44%195813249350.000+90%
Usd Price Per Share187.630-12%209.520189.055+11%155.215+35%165.453+27%145.230+44%110.531+90%
Usd Profit--1286000000.0001048750000.000+23%1498250000.000-14%1481083333.333-13%1770550000.000-27%1684350000.000-24%
Usd Revenue--13343000000.00014341750000.000-7%13600750000.000-2%14042583333.333-5%13771550000.000-3%10543550000.000+27%
Usd Total Gains Per Share--0.5780.649-11%0.765-24%0.808-28%1.653-65%1.042-45%
 EOD+4 -4MRQTTM+18 -21YOY+13 -273Y+12 -285Y+12 -2810Y+13 -27

3.3 Fundamental Score

Let's check the fundamental score of AbbVie Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1564.635
Price to Book Ratio (EOD)Between0-1227.415
Net Profit Margin (MRQ)Greater than00.096
Operating Margin (MRQ)Greater than00.127
Quick Ratio (MRQ)Greater than10.485
Current Ratio (MRQ)Greater than10.760
Debt to Asset Ratio (MRQ)Less than10.989
Debt to Equity Ratio (MRQ)Less than194.861
Return on Equity (MRQ)Greater than0.150.906
Return on Assets (MRQ)Greater than0.050.009
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of AbbVie Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.675
Ma 20Greater thanMa 50187.885
Ma 50Greater thanMa 100187.347
Ma 100Greater thanMa 200192.866
OpenGreater thanClose189.440
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Fundamental data was last updated by Penke on 2025-06-18 21:53:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Abbvie earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 9.6% means that $0.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AbbVie Inc:

  • The MRQ is 9.6%. The company is making a profit. +1
  • The TTM is 7.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.6%TTM7.4%+2.2%
TTM7.4%YOY11.1%-3.6%
TTM7.4%5Y12.6%-5.1%
5Y12.6%10Y17.3%-4.7%
4.3.1.2. Return on Assets

Shows how efficient Abbvie is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • 0.9% Return on Assets means that Abbvie generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AbbVie Inc:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.7%+0.2%
TTM0.7%YOY1.1%-0.3%
TTM0.7%5Y1.2%-0.5%
5Y1.2%10Y1.8%-0.6%
4.3.1.3. Return on Equity

Shows how efficient Abbvie is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • 90.6% Return on Equity means Abbvie generated $0.91 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AbbVie Inc:

  • The MRQ is 90.6%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 34.0%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ90.6%TTM34.0%+56.6%
TTM34.0%YOY13.9%+20.1%
TTM34.0%5Y17.9%+16.1%
5Y17.9%10Y18.2%-0.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AbbVie Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Abbvie is operating .

  • Measures how much profit Abbvie makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 12.7% means the company generated $0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AbbVie Inc:

  • The MRQ is 12.7%. The company is operating less efficient.
  • The TTM is 14.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ12.7%TTM14.2%-1.5%
TTM14.2%YOY28.4%-14.2%
TTM14.2%5Y29.7%-15.5%
5Y29.7%10Y34.3%-4.5%
4.3.2.2. Operating Ratio

Measures how efficient Abbvie is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.72 means that the operating costs are $0.72 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AbbVie Inc:

  • The MRQ is 0.720. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.800. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.720TTM0.800-0.079
TTM0.800YOY0.732+0.068
TTM0.8005Y0.727+0.072
5Y0.72710Y0.694+0.033
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AbbVie Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Abbvie is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.76 means the company has $0.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AbbVie Inc:

  • The MRQ is 0.760. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.718. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.760TTM0.718+0.042
TTM0.718YOY0.915-0.197
TTM0.7185Y0.862-0.144
5Y0.86210Y1.214-0.351
4.4.3.2. Quick Ratio

Measures if Abbvie is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.48 means the company can pay off $0.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AbbVie Inc:

  • The MRQ is 0.485. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.485. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.485TTM0.4850.000
TTM0.485YOY0.674-0.189
TTM0.4855Y0.620-0.134
5Y0.62010Y0.957-0.338
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AbbVie Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Abbvie assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abbvie to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.99 means that Abbvie assets are financed with 98.9% credit (debt) and the remaining percentage (100% - 98.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AbbVie Inc:

  • The MRQ is 0.989. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.968. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.989TTM0.968+0.021
TTM0.968YOY0.921+0.047
TTM0.9685Y0.917+0.051
5Y0.91710Y0.955-0.038
4.5.4.2. Debt to Equity Ratio

Measures if Abbvie is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 9,486.1% means that company has $94.86 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AbbVie Inc:

  • The MRQ is 94.861. The company is unable to pay all its debts with equity. -1
  • The TTM is 44.301. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ94.861TTM44.301+50.560
TTM44.301YOY12.342+31.959
TTM44.3015Y16.743+27.558
5Y16.74310Y11.835+4.908
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Abbvie generates.

  • Above 15 is considered overpriced but always compare Abbvie to the Drug Manufacturers - General industry mean.
  • A PE ratio of 72.18 means the investor is paying $72.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AbbVie Inc:

  • The EOD is 64.635. Based on the earnings, the company is expensive. -2
  • The MRQ is 72.175. Based on the earnings, the company is expensive. -2
  • The TTM is -849.150. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD64.635MRQ72.175-7.541
MRQ72.175TTM-849.150+921.326
TTM-849.150YOY52.325-901.475
TTM-849.1505Y-68.268-780.883
5Y-68.26810Y-5.648-62.620
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AbbVie Inc:

  • The EOD is 59.371. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 66.298. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 33.049. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD59.371MRQ66.298-6.927
MRQ66.298TTM33.049+33.250
TTM33.049YOY13.691+19.358
TTM33.0495Y16.169+16.879
5Y16.16910Y15.137+1.033
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Abbvie is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 253.95 means the investor is paying $253.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AbbVie Inc:

  • The EOD is 227.415. Based on the equity, the company is expensive. -2
  • The MRQ is 253.946. Based on the equity, the company is expensive. -2
  • The TTM is 112.444. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD227.415MRQ253.946-26.532
MRQ253.946TTM112.444+141.502
TTM112.444YOY26.700+85.745
TTM112.4445Y37.082+75.362
5Y37.08210Y20.710+16.373
4.6.2. Total Gains per Share

2.4. Latest News of AbbVie Inc

Does AbbVie Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from AbbVie Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-07
18:18
Prime Medicine stock soars amid gene editing sector momentumRead
2025-07-07
15:00
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on ItRead
2025-07-06
19:03
Guru Fundamental Report for ABBVRead
2025-07-06
15:05
Notable healthcare headlines for the week: Novo Nordisk, Eli Lilly, AbbVie and Centene in focusRead
2025-07-05
11:41
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold ForeverRead
2025-07-05
11:41
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold ForeverRead
2025-07-04
15:09
Validea Detailed Fundamental Analysis - ABBVRead
2025-07-03
19:40
AbbVie sees negative Q2, full-year impact from IPR&D and milestones expenseRead
2025-07-03
19:25
AbbVie updates 2025 earnings guidance to reflect $823 million IPR&D expenseRead
2025-07-01
22:31
Top Stock Reports for Alphabet, AbbVie & Walt DisneyRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AbbVie Inc.

4.8.1. Institutions holding AbbVie Inc

Institutions are holding 74.461% of the shares of AbbVie Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc9.84590.65881739178658457870.4887
2025-03-31BlackRock Inc8.25850.64214587814238425772.7054
2025-03-31State Street Corp4.52690.6904799629673414800.4289
2025-03-31JPMorgan Chase & Co3.09980.83775475447029919795.7802
2025-03-31Morgan Stanley - Brokerage Accounts2.32960.61654114973414605703.68
2025-03-31Geode Capital Management, LLC2.16560.62813825359011086572.9847
2025-03-31Capital Research Global Investors1.8971.526633508014-475693-1.3998
2025-03-31Bank of America Corp1.58250.473227953530262956510.3837
2025-03-31Charles Schwab Investment Management Inc1.43040.992125266107-2170026-7.9094
2024-12-31NORGES BANK1.42070.585225095020261655511.6403
2025-03-31FMR Inc1.33810.316223636582553920730.6078
2025-03-31Northern Trust Corp1.24630.6848220139201892940.8673
2025-03-31Capital Research & Mgmt Co - Division 31.16260.845920536730-7996758-28.0259
2025-03-31Franklin Resources Inc1.00041.0652176706344237342.4569
2025-03-31Capital World Investors0.91520.548716165653-244624-1.4907
2025-03-31Goldman Sachs Group Inc0.80110.479914150008285478725.2743
2025-03-31Bank of New York Mellon Corp0.74940.549313237703-426197-3.1191
2025-03-31UBS Asset Mgmt Americas Inc0.7230.6852127718547131485.914
2024-12-31UBS Group AG0.71220.41321258020810861029.4492
2025-03-31Ameriprise Financial Inc0.70170.701212395341-635327-4.8756
Total 45.906913.9402810898072+14694817+1.8%

4.9.2. Funds holding AbbVie Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv3.20670.6431566430418457501.5158
2025-04-30Vanguard Institutional 500 Index Trust2.82270.7292498606947963461.6231
2025-04-30Fidelity 500 Index1.25540.728422175573273780.1236
2025-05-31SPDR® S&P 500® ETF1.19420.65421094959-94276-0.4449
2025-05-31iShares Core S&P 500 ETF1.15750.65372044642000
2025-04-30Vanguard Value Index Inv0.87711.64731549325339020.0252
2025-03-31Capital Group American Mutual Comp0.87653.171515483326-2538418-14.0853
2025-03-31American Funds American Mutual A0.87653.171515483326-2538418-14.0853
2025-05-31Schwab US Dividend Equity ETF™0.77263.72341364646494320.0692
2025-05-31The Health Care Select Sector SPDR® ETF0.70986.814612537994-77792-0.6166
2025-03-31Capital Group Wash Mutual Invtrs Comp0.65681.302711601403-1680167-12.6504
2025-03-31American Funds Washington Mutual A0.65681.302711601403-1680167-12.6504
2025-03-31American Funds Capital Income Bldr A0.61372.076510840883-1301422-10.7181
2025-04-30Vanguard Institutional Index I0.61360.728910837771-27674-0.2547
2025-04-30Vanguard Dividend Appreciation ETF0.5351.811394509041060411.1348
2025-05-31State St S&P 500® Indx SL Cl III0.53090.64993779591584001.7181
2025-03-31American Funds Invmt Co of Amer A0.47891.201584592195501716.9562
2025-03-31Capital Group Investment Co of Amer Comp0.47891.201584592195501716.9562
2025-04-30Vanguard High Dividend Yield ETF0.38121.86826734307-10006-0.1484
2025-03-31Blackrock Eq Idx Fund CF0.37370.7716601108-26715-0.4031
Total 19.068534.85336829226-6927464-2.1%

5.3. Insider Transactions

Insiders are holding 0.104% of the shares of AbbVie Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-31Jeffrey Ryan StewartSELL58832210.08
2025-02-26Timothy J RichmondSELL29917202.9
2025-02-26Kevin K BuckbeeSELL18944203.41
2025-02-20Perry C SiatisSELL5778197.9
2024-12-16Kevin K BuckbeeSELL1800172.24
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets136,165,000
Total Liabilities134,703,000
Total Stockholder Equity1,420,000
 As reported
Total Liabilities 134,703,000
Total Stockholder Equity+ 1,420,000
Total Assets = 136,165,000

Assets

Total Assets136,165,000
Total Current Assets27,675,000
Long-term Assets108,490,000
Total Current Assets
Cash And Cash Equivalents 5,175,000
Short-term Investments 1,000
Net Receivables 12,477,000
Inventory 4,526,000
Other Current Assets 5,496,000
Total Current Assets  (as reported)27,675,000
Total Current Assets  (calculated)27,675,000
+/-0
Long-term Assets
Property Plant Equipment 5,237,000
Goodwill 35,285,000
Long Term Investments 287,000
Intangible Assets 58,489,000
Long-term Assets Other 9,192,000
Long-term Assets  (as reported)108,490,000
Long-term Assets  (calculated)108,490,000
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36,403,000
Long-term Liabilities98,300,000
Total Stockholder Equity1,420,000
Total Current Liabilities
Short-term Debt 5,362,000
Short Long Term Debt 5,362,000
Other Current Liabilities 31,041,000
Total Current Liabilities  (as reported)36,403,000
Total Current Liabilities  (calculated)41,765,000
+/- 5,362,000
Long-term Liabilities
Long term Debt 64,527,000
Long-term Liabilities Other 31,191,000
Long-term Liabilities  (as reported)98,300,000
Long-term Liabilities  (calculated)95,718,000
+/- 2,582,000
Total Stockholder Equity
Common Stock18,000
Retained Earnings -9,527,000
Accumulated Other Comprehensive Income -1,742,000
Other Stockholders Equity 12,671,000
Total Stockholder Equity (as reported)1,420,000
Total Stockholder Equity (calculated)1,420,000
+/-0
Other
Capital Stock18,000
Cash and Short Term Investments 5,176,000
Common Stock Shares Outstanding 1,772,000
Liabilities and Stockholders Equity 136,165,000
Net Debt 64,714,000
Net Invested Capital 71,309,000
Net Working Capital -8,728,000
Property Plant and Equipment Gross 12,571,000
Short Long Term Debt Total 69,889,000



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-31
> Total Assets 
21,134,705
0
0
0
19,521,000
18,961,563
17,709,554
22,729,979
27,008,000
27,169,000
27,910,000
28,252,000
29,198,000
28,657,000
29,045,000
28,454,000
27,513,000
26,699,000
53,855,000
54,832,000
53,050,000
53,720,000
67,211,000
66,626,000
66,099,000
65,664,000
66,994,000
68,840,000
70,786,000
69,342,000
61,641,000
66,164,000
59,352,000
56,769,000
57,142,000
59,441,000
89,115,000
91,199,000
149,530,000
149,621,000
150,565,000
150,501,000
147,972,000
148,858,000
146,529,000
143,211,000
143,186,000
141,325,000
138,805,000
134,544,000
135,367,000
136,221,000
134,711,000
148,874,000
141,937,000
143,422,000
135,161,000
136,165,000
136,165,000135,161,000143,422,000141,937,000148,874,000134,711,000136,221,000135,367,000134,544,000138,805,000141,325,000143,186,000143,211,000146,529,000148,858,000147,972,000150,501,000150,565,000149,621,000149,530,00091,199,00089,115,00059,441,00057,142,00056,769,00059,352,00066,164,00061,641,00069,342,00070,786,00068,840,00066,994,00065,664,00066,099,00066,626,00067,211,00053,720,00053,050,00054,832,00053,855,00026,699,00027,513,00028,454,00029,045,00028,657,00029,198,00028,252,00027,910,00027,169,00027,008,00022,729,97917,709,55418,961,56319,521,00000021,134,705
   > Total Current Assets 
0
0
0
0
7,354,000
6,751,048
5,992,960
10,930,739
15,354,000
14,923,000
15,662,000
16,543,000
17,848,000
17,329,000
17,794,000
17,555,000
16,081,000
15,408,000
16,877,000
17,912,000
16,314,000
16,622,000
16,791,000
16,290,000
16,187,000
15,547,000
16,962,000
18,930,000
21,223,000
20,444,000
13,845,000
18,465,000
16,945,000
14,413,000
15,100,000
20,166,000
49,519,000
51,758,000
21,256,000
23,009,000
24,173,000
26,569,000
25,999,000
28,957,000
27,928,000
26,509,000
29,100,000
30,364,000
28,463,000
26,488,000
28,852,000
33,224,000
33,002,000
38,871,000
33,816,000
27,785,000
25,582,000
27,675,000
27,675,00025,582,00027,785,00033,816,00038,871,00033,002,00033,224,00028,852,00026,488,00028,463,00030,364,00029,100,00026,509,00027,928,00028,957,00025,999,00026,569,00024,173,00023,009,00021,256,00051,758,00049,519,00020,166,00015,100,00014,413,00016,945,00018,465,00013,845,00020,444,00021,223,00018,930,00016,962,00015,547,00016,187,00016,290,00016,791,00016,622,00016,314,00017,912,00016,877,00015,408,00016,081,00017,555,00017,794,00017,329,00017,848,00016,543,00015,662,00014,923,00015,354,00010,930,7395,992,9606,751,0487,354,0000000
       Cash And Cash Equivalents 
9,644
0
0
0
27,000
40,999
74,537
2,760,988
5,901,000
6,979,000
8,743,000
8,975,000
9,595,000
8,140,000
9,086,000
7,719,000
8,348,000
7,906,000
7,400,000
9,223,000
8,399,000
7,556,000
6,327,000
6,218,000
5,100,000
4,740,000
6,088,000
8,446,000
9,303,000
9,007,000
3,547,000
8,015,000
7,289,000
4,897,000
5,172,000
10,648,000
39,924,000
41,142,000
6,017,000
7,890,000
8,449,000
9,755,000
8,546,000
12,182,000
9,746,000
6,098,000
8,521,000
11,832,000
9,201,000
6,711,000
8,759,000
13,287,000
12,814,000
18,067,000
13,130,000
7,257,000
5,524,000
5,175,000
5,175,0005,524,0007,257,00013,130,00018,067,00012,814,00013,287,0008,759,0006,711,0009,201,00011,832,0008,521,0006,098,0009,746,00012,182,0008,546,0009,755,0008,449,0007,890,0006,017,00041,142,00039,924,00010,648,0005,172,0004,897,0007,289,0008,015,0003,547,0009,007,0009,303,0008,446,0006,088,0004,740,0005,100,0006,218,0006,327,0007,556,0008,399,0009,223,0007,400,0007,906,0008,348,0007,719,0009,086,0008,140,0009,595,0008,975,0008,743,0006,979,0005,901,0002,760,98874,53740,99927,0000009,644
       Short-term Investments 
1,873,621
0
0
0
626,000
1,992
0
1,824,617
2,075,000
500,000
11,000
621,000
300,000
960,000
1,160,000
9,000
26,000
18,000
879,000
26,000
8,000
1,044,000
1,675,000
1,732,000
1,323,000
1,508,000
1,117,000
1,108,000
486,000
467,000
196,000
770,000
772,000
331,000
244,000
0
0
0
23,000
60,000
30,000
22,000
54,000
67,000
84,000
1,474,000
1,440,000
47,000
28,000
11,000
7,000
3,000
2,000
2,000
27,000
28,000
31,000
1,000
1,00031,00028,00027,0002,0002,0003,0007,00011,00028,00047,0001,440,0001,474,00084,00067,00054,00022,00030,00060,00023,000000244,000331,000772,000770,000196,000467,000486,0001,108,0001,117,0001,508,0001,323,0001,732,0001,675,0001,044,0008,00026,000879,00018,00026,0009,0001,160,000960,000300,000621,00011,000500,0002,075,0001,824,61701,992626,0000001,873,621
       Net Receivables 
0
0
0
0
3,817,000
3,646,763
2,994,005
3,097,510
4,298,000
4,299,000
3,755,000
3,798,000
3,116,000
3,110,000
3,128,000
3,064,000
3,735,000
4,214,000
4,367,000
4,574,000
4,730,000
4,753,000
5,048,000
4,999,000
4,758,000
4,677,000
4,859,000
4,891,000
5,088,000
5,841,000
5,793,000
5,780,000
5,384,000
5,680,000
5,482,000
5,529,000
5,428,000
6,362,000
8,354,000
8,416,000
8,822,000
9,588,000
9,914,000
9,281,000
9,977,000
10,733,000
11,237,000
10,743,000
11,254,000
11,473,000
11,491,000
11,412,000
11,155,000
11,949,000
11,724,000
11,472,000
10,919,000
12,477,000
12,477,00010,919,00011,472,00011,724,00011,949,00011,155,00011,412,00011,491,00011,473,00011,254,00010,743,00011,237,00010,733,0009,977,0009,281,0009,914,0009,588,0008,822,0008,416,0008,354,0006,362,0005,428,0005,529,0005,482,0005,680,0005,384,0005,780,0005,793,0005,841,0005,088,0004,891,0004,859,0004,677,0004,758,0004,999,0005,048,0004,753,0004,730,0004,574,0004,367,0004,214,0003,735,0003,064,0003,128,0003,110,0003,116,0003,798,0003,755,0004,299,0004,298,0003,097,5102,994,0053,646,7633,817,0000000
       Inventory 
836,270
0
0
0
872,000
915,794
862,775
958,878
1,091,000
1,037,000
1,085,000
1,172,000
1,150,000
1,104,000
1,048,000
1,008,000
1,124,000
1,022,000
1,623,000
1,841,000
1,719,000
1,789,000
1,756,000
1,630,000
1,444,000
1,427,000
1,582,000
1,785,000
1,605,000
1,738,000
1,580,000
1,786,000
1,605,000
1,702,000
1,895,000
1,929,000
1,813,000
1,844,000
4,059,000
3,474,000
3,310,000
3,272,000
3,386,000
3,094,000
3,128,000
3,483,000
3,396,000
3,172,000
3,579,000
3,833,000
4,055,000
3,981,000
4,099,000
4,245,000
4,218,000
4,450,000
4,181,000
4,526,000
4,526,0004,181,0004,450,0004,218,0004,245,0004,099,0003,981,0004,055,0003,833,0003,579,0003,172,0003,396,0003,483,0003,128,0003,094,0003,386,0003,272,0003,310,0003,474,0004,059,0001,844,0001,813,0001,929,0001,895,0001,702,0001,605,0001,786,0001,580,0001,738,0001,605,0001,785,0001,582,0001,427,0001,444,0001,630,0001,756,0001,789,0001,719,0001,841,0001,623,0001,022,0001,124,0001,008,0001,048,0001,104,0001,150,0001,172,0001,085,0001,037,0001,091,000958,878862,775915,794872,000000836,270
   > Long-term Assets 
0
0
0
0
12,167,000
12,210,515
11,716,594
11,799,240
11,654,000
12,246,000
12,248,000
11,709,000
11,350,000
11,328,000
11,251,000
10,899,000
11,432,000
11,291,000
36,978,000
36,920,000
36,736,000
37,098,000
50,420,000
50,336,000
49,912,000
50,117,000
50,032,000
49,910,000
49,563,000
48,898,000
47,796,000
47,699,000
42,407,000
42,356,000
42,042,000
39,275,000
39,596,000
39,441,000
128,274,000
126,612,000
126,392,000
123,932,000
121,973,000
119,901,000
118,601,000
116,702,000
114,086,000
110,961,000
110,342,000
108,056,000
106,515,000
102,997,000
101,709,000
110,003,000
108,121,000
115,637,000
109,579,000
108,490,000
108,490,000109,579,000115,637,000108,121,000110,003,000101,709,000102,997,000106,515,000108,056,000110,342,000110,961,000114,086,000116,702,000118,601,000119,901,000121,973,000123,932,000126,392,000126,612,000128,274,00039,441,00039,596,00039,275,00042,042,00042,356,00042,407,00047,699,00047,796,00048,898,00049,563,00049,910,00050,032,00050,117,00049,912,00050,336,00050,420,00037,098,00036,736,00036,920,00036,978,00011,291,00011,432,00010,899,00011,251,00011,328,00011,350,00011,709,00012,248,00012,246,00011,654,00011,799,24011,716,59412,210,51512,167,0000000
       Property Plant Equipment 
2,357,563
0
0
0
2,144,000
2,168,582
2,092,021
2,138,898
2,247,000
2,200,000
2,213,000
2,244,000
2,298,000
2,333,000
2,387,000
2,432,000
2,485,000
2,431,000
2,517,000
2,546,000
2,565,000
2,597,000
2,618,000
2,638,000
2,604,000
2,612,000
2,657,000
2,697,000
2,803,000
2,828,000
2,787,000
2,950,000
2,883,000
2,860,000
2,879,000
2,894,000
2,962,000
2,961,000
4,908,000
4,986,000
5,248,000
5,193,000
5,161,000
5,130,000
5,110,000
5,075,000
4,958,000
4,893,000
4,935,000
4,931,000
4,943,000
4,934,000
4,989,000
4,980,000
5,023,000
5,141,000
5,134,000
5,237,000
5,237,0005,134,0005,141,0005,023,0004,980,0004,989,0004,934,0004,943,0004,931,0004,935,0004,893,0004,958,0005,075,0005,110,0005,130,0005,161,0005,193,0005,248,0004,986,0004,908,0002,961,0002,962,0002,894,0002,879,0002,860,0002,883,0002,950,0002,787,0002,828,0002,803,0002,697,0002,657,0002,612,0002,604,0002,638,0002,618,0002,597,0002,565,0002,546,0002,517,0002,431,0002,485,0002,432,0002,387,0002,333,0002,298,0002,244,0002,213,0002,200,0002,247,0002,138,8982,092,0212,168,5822,144,0000002,357,563
       Goodwill 
6,197,182
0
0
0
6,100,000
6,164,149
5,973,558
6,092,202
6,130,000
6,060,000
6,120,000
6,199,000
6,277,000
6,271,000
6,244,000
6,002,000
5,862,000
5,534,000
13,209,000
13,243,000
13,168,000
13,274,000
15,507,000
15,657,000
15,416,000
15,490,000
15,652,000
15,748,000
15,785,000
15,880,000
15,692,000
15,718,000
15,663,000
15,606,000
15,642,000
15,537,000
15,604,000
15,561,000
42,669,000
42,801,000
33,124,000
32,349,000
32,398,000
32,296,000
32,379,000
32,298,000
32,028,000
31,726,000
32,156,000
32,220,000
32,224,000
32,091,000
32,293,000
33,426,000
33,386,000
35,295,000
34,956,000
35,285,000
35,285,00034,956,00035,295,00033,386,00033,426,00032,293,00032,091,00032,224,00032,220,00032,156,00031,726,00032,028,00032,298,00032,379,00032,296,00032,398,00032,349,00033,124,00042,801,00042,669,00015,561,00015,604,00015,537,00015,642,00015,606,00015,663,00015,718,00015,692,00015,880,00015,785,00015,748,00015,652,00015,490,00015,416,00015,657,00015,507,00013,274,00013,168,00013,243,00013,209,0005,534,0005,862,0006,002,0006,244,0006,271,0006,277,0006,199,0006,120,0006,060,0006,130,0006,092,2025,973,5586,164,1496,100,0000006,197,182
       Long Term Investments 
0
0
0
0
0
0
0
0
0
118,000
121,000
123,000
118,000
119,000
130,000
124,000
92,000
93,000
134,000
74,000
145,000
387,000
1,400,000
1,378,000
1,783,000
2,123,000
2,052,000
1,971,000
2,090,000
2,057,000
1,505,000
1,463,000
1,420,000
1,477,000
1,473,000
131,000
93,000
78,000
225,000
246,000
293,000
305,000
266,000
272,000
277,000
260,000
244,000
235,000
241,000
257,000
288,000
275,000
304,000
305,000
272,000
267,000
279,000
287,000
287,000279,000267,000272,000305,000304,000275,000288,000257,000241,000235,000244,000260,000277,000272,000266,000305,000293,000246,000225,00078,00093,000131,0001,473,0001,477,0001,420,0001,463,0001,505,0002,057,0002,090,0001,971,0002,052,0002,123,0001,783,0001,378,0001,400,000387,000145,00074,000134,00093,00092,000124,000130,000119,000118,000123,000121,000118,000000000000
       Intangible Assets 
9,888,360
0
0
0
2,910,000
2,744,549
2,540,297
2,431,057
2,323,000
2,153,000
2,101,000
1,993,000
1,890,000
1,802,000
1,695,000
1,540,000
1,513,000
1,478,000
19,937,000
19,822,000
19,709,000
19,512,000
29,450,000
29,113,000
28,897,000
28,629,000
28,366,000
28,167,000
27,559,000
27,230,000
26,903,000
26,625,000
21,233,000
20,846,000
20,459,000
19,036,000
18,649,000
18,203,000
76,463,000
74,643,000
82,876,000
81,293,000
79,340,000
77,456,000
75,951,000
73,986,000
71,823,000
68,725,000
67,439,000
64,848,000
62,862,000
58,603,000
55,610,000
62,225,000
60,243,000
66,646,000
60,068,000
58,489,000
58,489,00060,068,00066,646,00060,243,00062,225,00055,610,00058,603,00062,862,00064,848,00067,439,00068,725,00071,823,00073,986,00075,951,00077,456,00079,340,00081,293,00082,876,00074,643,00076,463,00018,203,00018,649,00019,036,00020,459,00020,846,00021,233,00026,625,00026,903,00027,230,00027,559,00028,167,00028,366,00028,629,00028,897,00029,113,00029,450,00019,512,00019,709,00019,822,00019,937,0001,478,0001,513,0001,540,0001,695,0001,802,0001,890,0001,993,0002,101,0002,153,0002,323,0002,431,0572,540,2972,744,5492,910,0000009,888,360
       Long-term Assets Other 
0
0
0
0
-135,650
0
0
0
835,000
1,715,000
1,693,000
1,150,000
767,000
803,000
795,000
801,000
1,480,000
1,755,000
1,181,000
1,235,000
1,149,000
1,328,000
1,445,000
1,550,000
1,212,000
1,263,000
1,305,000
1,327,000
1,326,000
903,000
909,000
943,000
1,208,000
1,567,000
1,589,000
1,677,000
2,288,000
2,638,000
4,009,000
3,936,000
4,851,000
4,792,000
4,808,000
4,747,000
4,884,000
5,083,000
5,033,000
5,382,000
5,571,000
5,800,000
6,198,000
7,094,000
8,513,000
9,067,000
9,197,000
8,288,000
9,142,000
9,192,000
9,192,0009,142,0008,288,0009,197,0009,067,0008,513,0007,094,0006,198,0005,800,0005,571,0005,382,0005,033,0005,083,0004,884,0004,747,0004,808,0004,792,0004,851,0003,936,0004,009,0002,638,0002,288,0001,677,0001,589,0001,567,0001,208,000943,000909,000903,0001,326,0001,327,0001,305,0001,263,0001,212,0001,550,0001,445,0001,328,0001,149,0001,235,0001,181,0001,755,0001,480,000801,000795,000803,000767,0001,150,0001,693,0001,715,000835,000000-135,6500000
> Total Liabilities 
5,431,706
0
0
0
7,589,000
6,910,794
6,204,479
7,061,143
23,645,000
24,212,000
24,352,000
24,675,000
24,706,000
23,960,000
23,827,000
23,809,000
25,771,000
25,322,000
48,351,000
49,969,000
49,105,000
49,077,000
61,571,000
60,157,000
61,463,000
60,666,000
60,985,000
62,153,000
65,689,000
65,789,000
65,016,000
69,085,000
67,798,000
64,595,000
65,708,000
67,667,000
97,287,000
98,614,000
134,798,000
134,332,000
137,468,000
136,768,000
135,378,000
135,281,000
131,093,000
126,897,000
128,498,000
125,298,000
121,518,000
121,241,000
122,469,000
124,092,000
124,314,000
140,827,000
135,116,000
137,351,000
131,797,000
134,703,000
134,703,000131,797,000137,351,000135,116,000140,827,000124,314,000124,092,000122,469,000121,241,000121,518,000125,298,000128,498,000126,897,000131,093,000135,281,000135,378,000136,768,000137,468,000134,332,000134,798,00098,614,00097,287,00067,667,00065,708,00064,595,00067,798,00069,085,00065,016,00065,789,00065,689,00062,153,00060,985,00060,666,00061,463,00060,157,00061,571,00049,077,00049,105,00049,969,00048,351,00025,322,00025,771,00023,809,00023,827,00023,960,00024,706,00024,675,00024,352,00024,212,00023,645,0007,061,1436,204,4796,910,7947,589,0000005,431,706
   > Total Current Liabilities 
3,761,248
0
0
0
5,897,000
5,514,959
4,839,721
5,367,892
6,776,000
6,766,000
6,805,000
6,875,000
6,879,000
6,216,000
6,317,000
6,635,000
11,393,000
11,050,000
11,258,000
8,813,000
10,894,000
10,662,000
9,272,000
9,103,000
9,781,000
8,844,000
12,259,000
13,033,000
16,641,000
17,058,000
17,224,000
15,387,000
17,239,000
13,904,000
16,941,000
17,493,000
15,585,000
16,471,000
24,646,000
24,181,000
28,661,000
31,951,000
28,684,000
28,533,000
35,194,000
32,521,000
34,473,000
32,712,000
29,538,000
27,590,000
32,239,000
34,773,000
37,841,000
41,522,000
41,915,000
43,062,000
38,749,000
36,403,000
36,403,00038,749,00043,062,00041,915,00041,522,00037,841,00034,773,00032,239,00027,590,00029,538,00032,712,00034,473,00032,521,00035,194,00028,533,00028,684,00031,951,00028,661,00024,181,00024,646,00016,471,00015,585,00017,493,00016,941,00013,904,00017,239,00015,387,00017,224,00017,058,00016,641,00013,033,00012,259,0008,844,0009,781,0009,103,0009,272,00010,662,00010,894,0008,813,00011,258,00011,050,00011,393,0006,635,0006,317,0006,216,0006,879,0006,875,0006,805,0006,766,0006,776,0005,367,8924,839,7215,514,9595,897,0000003,761,248
       Short-term Debt 
0
0
0
0
16,000
0
0
0
1,042,000
436,000
432,000
434,000
431,000
20,000
271,000
323,000
4,439,000
4,590,000
4,007,000
768,000
2,431,000
2,423,000
517,000
26,000
402,000
425,000
3,420,000
3,821,000
6,415,000
6,381,000
6,530,000
4,021,000
5,308,000
2,198,000
5,761,000
5,390,000
3,869,000
3,762,000
5,371,000
4,777,000
8,685,000
11,347,000
7,901,000
6,672,000
12,495,000
9,952,000
11,930,000
9,207,000
4,136,000
2,801,000
5,203,000
5,115,000
7,191,000
10,196,000
12,586,000
12,570,000
6,804,000
5,362,000
5,362,0006,804,00012,570,00012,586,00010,196,0007,191,0005,115,0005,203,0002,801,0004,136,0009,207,00011,930,0009,952,00012,495,0006,672,0007,901,00011,347,0008,685,0004,777,0005,371,0003,762,0003,869,0005,390,0005,761,0002,198,0005,308,0004,021,0006,530,0006,381,0006,415,0003,821,0003,420,000425,000402,00026,000517,0002,423,0002,431,000768,0004,007,0004,590,0004,439,000323,000271,00020,000431,000434,000432,000436,0001,042,00000016,0000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,014,000
0
0
0
2,025,000
2,423,000
517,000
26,000
25,000
425,000
37,543,000
3,021,000
6,015,000
6,024,000
3,026,000
1,026,000
1,609,000
2,078,000
5,641,000
5,276,000
3,753,000
3,762,000
5,371,000
4,777,000
8,502,000
11,347,000
7,901,000
6,672,000
12,495,000
9,952,000
11,930,000
9,207,000
4,136,000
2,801,000
5,203,000
5,115,000
7,191,000
10,196,000
12,586,000
12,570,000
6,804,000
5,362,000
5,362,0006,804,00012,570,00012,586,00010,196,0007,191,0005,115,0005,203,0002,801,0004,136,0009,207,00011,930,0009,952,00012,495,0006,672,0007,901,00011,347,0008,502,0004,777,0005,371,0003,762,0003,753,0005,276,0005,641,0002,078,0001,609,0001,026,0003,026,0006,024,0006,015,0003,021,00037,543,000425,00025,00026,000517,0002,423,0002,025,0000004,014,0000000000000000000
       Accounts payable 
356,784
0
0
0
417,000
476,129
337,118
423,907
556,000
6,330,000
6,373,000
6,441,000
933,000
6,196,000
6,046,000
6,312,000
1,401,000
6,460,000
7,251,000
8,045,000
1,597,000
8,239,000
8,755,000
9,077,000
1,407,000
8,419,000
8,839,000
9,212,000
1,474,000
10,677,000
10,694,000
11,366,000
1,546,000
11,826,000
11,300,000
12,217,000
1,452,000
12,709,000
19,275,000
19,404,000
2,276,000
20,604,000
20,200,000
21,861,000
2,882,000
22,569,000
22,108,000
23,389,000
2,934,000
24,654,000
26,905,000
29,570,000
3,688,000
31,258,000
29,296,000
30,398,000
2,945,000
0
02,945,00030,398,00029,296,00031,258,0003,688,00029,570,00026,905,00024,654,0002,934,00023,389,00022,108,00022,569,0002,882,00021,861,00020,200,00020,604,0002,276,00019,404,00019,275,00012,709,0001,452,00012,217,00011,300,00011,826,0001,546,00011,366,00010,694,00010,677,0001,474,0009,212,0008,839,0008,419,0001,407,0009,077,0008,755,0008,239,0001,597,0008,045,0007,251,0006,460,0001,401,0006,312,0006,046,0006,196,000933,0006,441,0006,373,0006,330,000556,000423,907337,118476,129417,000000356,784
       Other Current Liabilities 
3,404,464
0
0
0
5,464,000
5,038,830
4,502,603
4,943,985
5,178,000
6,330,000
6,373,000
6,441,000
5,515,000
6,196,000
6,046,000
6,312,000
5,553,000
6,460,000
7,251,000
8,045,000
6,866,000
8,239,000
8,755,000
9,077,000
7,972,000
8,419,000
8,839,000
9,212,000
8,752,000
10,677,000
10,694,000
11,366,000
10,385,000
11,706,000
11,180,000
12,103,000
10,264,000
12,709,000
19,275,000
19,404,000
17,700,000
20,604,000
20,783,000
21,861,000
19,817,000
22,569,000
22,543,000
23,505,000
22,468,000
24,789,000
27,036,000
29,658,000
26,962,000
31,326,000
29,329,000
30,492,000
2,971,000
31,041,000
31,041,0002,971,00030,492,00029,329,00031,326,00026,962,00029,658,00027,036,00024,789,00022,468,00023,505,00022,543,00022,569,00019,817,00021,861,00020,783,00020,604,00017,700,00019,404,00019,275,00012,709,00010,264,00012,103,00011,180,00011,706,00010,385,00011,366,00010,694,00010,677,0008,752,0009,212,0008,839,0008,419,0007,972,0009,077,0008,755,0008,239,0006,866,0008,045,0007,251,0006,460,0005,553,0006,312,0006,046,0006,196,0005,515,0006,441,0006,373,0006,330,0005,178,0004,943,9854,502,6035,038,8305,464,0000003,404,464
   > Long-term Liabilities 
0
0
0
0
1,692,000
1,395,835
1,364,758
1,693,251
16,869,000
17,446,000
17,547,000
17,800,000
17,827,000
17,744,000
17,510,000
17,174,000
14,378,000
14,272,000
37,093,000
41,156,000
38,211,000
38,415,000
52,299,000
51,054,000
51,682,000
51,822,000
48,726,000
49,120,000
49,048,000
48,731,000
47,792,000
53,698,000
50,559,000
50,691,000
48,767,000
50,174,000
81,702,000
82,143,000
110,152,000
110,151,000
108,807,000
104,817,000
106,694,000
106,748,000
95,899,000
94,376,000
94,025,000
92,586,000
91,980,000
93,651,000
90,230,000
89,319,000
86,473,000
99,305,000
93,201,000
94,289,000
93,048,000
98,300,000
98,300,00093,048,00094,289,00093,201,00099,305,00086,473,00089,319,00090,230,00093,651,00091,980,00092,586,00094,025,00094,376,00095,899,000106,748,000106,694,000104,817,000108,807,000110,151,000110,152,00082,143,00081,702,00050,174,00048,767,00050,691,00050,559,00053,698,00047,792,00048,731,00049,048,00049,120,00048,726,00051,822,00051,682,00051,054,00052,299,00038,415,00038,211,00041,156,00037,093,00014,272,00014,378,00017,174,00017,510,00017,744,00017,827,00017,800,00017,547,00017,446,00016,869,0001,693,2511,364,7581,395,8351,692,0000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
14,601,000
14,326,000
14,375,000
14,292,000
14,386,000
14,470,000
14,469,000
10,565,000
10,683,000
27,116,000
31,359,000
29,240,000
29,490,000
37,328,000
37,284,000
36,440,000
36,526,000
33,817,000
33,974,000
30,953,000
30,906,000
30,579,000
36,487,000
35,002,000
35,066,000
31,619,000
33,126,000
62,975,000
63,284,000
82,061,000
82,282,000
77,554,000
74,183,000
74,237,000
74,049,000
64,189,000
63,522,000
61,002,000
60,399,000
59,135,000
59,292,000
55,812,000
0
0
0
0
0
0
0
000000055,812,00059,292,00059,135,00060,399,00061,002,00063,522,00064,189,00074,049,00074,237,00074,183,00077,554,00082,282,00082,061,00063,284,00062,975,00033,126,00031,619,00035,066,00035,002,00036,487,00030,579,00030,906,00030,953,00033,974,00033,817,00036,526,00036,440,00037,284,00037,328,00029,490,00029,240,00031,359,00027,116,00010,683,00010,565,00014,469,00014,470,00014,386,00014,292,00014,375,00014,326,00014,601,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
2,845,000
3,221,000
3,425,000
3,535,000
3,358,000
3,040,000
2,705,000
3,840,000
3,589,000
3,918,000
3,801,000
3,695,000
3,513,000
7,791,000
7,646,000
8,352,000
8,499,000
8,518,000
8,999,000
15,605,000
15,521,000
15,543,000
15,721,000
14,490,000
14,509,000
16,000,000
15,990,000
17,597,000
17,900,000
23,306,000
23,384,000
27,607,000
26,866,000
28,796,000
29,097,000
28,701,000
28,023,000
30,768,000
30,215,000
30,655,000
32,249,000
32,294,000
31,644,000
28,607,000
32,778,000
32,427,000
33,031,000
27,634,000
31,191,000
31,191,00027,634,00033,031,00032,427,00032,778,00028,607,00031,644,00032,294,00032,249,00030,655,00030,215,00030,768,00028,023,00028,701,00029,097,00028,796,00026,866,00027,607,00023,384,00023,306,00017,900,00017,597,00015,990,00016,000,00014,509,00014,490,00015,721,00015,543,00015,521,00015,605,0008,999,0008,518,0008,499,0008,352,0007,646,0007,791,0003,513,0003,695,0003,801,0003,918,0003,589,0003,840,0002,705,0003,040,0003,358,0003,535,0003,425,0003,221,0002,845,000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,059,000
5,996,000
5,276,000
5,412,000
7,180,000
6,124,000
6,890,000
6,797,000
6,391,000
6,147,000
2,490,000
2,304,000
1,670,000
1,490,000
1,067,000
1,116,000
1,148,000
1,058,000
1,130,000
959,000
4,785,000
4,485,000
3,646,000
3,768,000
3,661,000
3,602,000
3,009,000
2,831,000
2,255,000
1,972,000
2,190,000
2,110,000
2,124,000
0
0
0
0
0
0
0
00000002,124,0002,110,0002,190,0001,972,0002,255,0002,831,0003,009,0003,602,0003,661,0003,768,0003,646,0004,485,0004,785,000959,0001,130,0001,058,0001,148,0001,116,0001,067,0001,490,0001,670,0002,304,0002,490,0006,147,0006,391,0006,797,0006,890,0006,124,0007,180,0005,412,0005,276,0005,996,0006,059,000000000000000000000
> Total Stockholder Equity
15,702,999
0
0
0
11,932,000
12,050,769
11,505,075
15,668,836
3,363,000
2,957,000
3,558,000
3,577,000
4,492,000
4,697,000
5,218,000
4,645,000
1,742,000
1,377,000
5,504,000
4,863,000
3,945,000
4,643,000
5,640,000
6,469,000
4,636,000
4,998,000
6,009,000
6,687,000
5,097,000
3,553,000
-3,375,000
-2,921,000
-8,446,000
-7,826,000
-8,566,000
-8,226,000
-8,172,000
-7,415,000
14,708,000
15,270,000
13,076,000
13,710,000
12,569,000
13,550,000
15,408,000
16,283,000
14,653,000
15,994,000
17,254,000
13,274,000
12,866,000
12,094,000
10,360,000
8,007,000
6,778,000
6,032,000
3,325,000
1,420,000
1,420,0003,325,0006,032,0006,778,0008,007,00010,360,00012,094,00012,866,00013,274,00017,254,00015,994,00014,653,00016,283,00015,408,00013,550,00012,569,00013,710,00013,076,00015,270,00014,708,000-7,415,000-8,172,000-8,226,000-8,566,000-7,826,000-8,446,000-2,921,000-3,375,0003,553,0005,097,0006,687,0006,009,0004,998,0004,636,0006,469,0005,640,0004,643,0003,945,0004,863,0005,504,0001,377,0001,742,0004,645,0005,218,0004,697,0004,492,0003,577,0003,558,0002,957,0003,363,00015,668,83611,505,07512,050,76911,932,00000015,702,999
   Common Stock
0
0
0
0
11,957,000
0
0
0
3,713,000
16,000
16,000
16,000
16,000
16,000
16,000
16,000
16,000
16,000
17,000
17,000
17,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,000
18,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00018,00017,00017,00017,00016,00016,00016,00016,00016,00016,00016,00016,00016,0003,713,00000011,957,0000000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
330,000
758,000
1,081,000
1,567,000
1,874,000
2,299,000
2,131,000
535,000
739,000
1,256,000
1,654,000
2,248,000
2,673,000
3,349,000
4,011,000
4,378,000
5,063,000
5,951,000
6,547,000
5,459,000
4,977,000
5,495,000
6,789,000
3,368,000
4,234,000
3,384,000
3,673,000
4,717,000
5,973,000
3,130,000
3,335,000
1,055,000
2,292,000
740,000
1,600,000
3,127,000
5,103,000
3,516,000
4,953,000
4,784,000
2,393,000
1,789,000
0
0
0
0
0
0
0
00000001,789,0002,393,0004,784,0004,953,0003,516,0005,103,0003,127,0001,600,000740,0002,292,0001,055,0003,335,0003,130,0005,973,0004,717,0003,673,0003,384,0004,234,0003,368,0006,789,0005,495,0004,977,0005,459,0006,547,0005,951,0005,063,0004,378,0004,011,0003,349,0002,673,0002,248,0001,654,0001,256,000739,000535,0002,131,0002,299,0001,874,0001,567,0001,081,000758,000330,000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-25,166
194,180
-325,493
-164,918
-350,000
-1,237,000
-1,169,000
-981,000
-442,000
-426,000
-420,000
-913,000
-2,031,000
-2,467,000
-2,374,000
-2,499,000
-2,561,000
-2,423,000
-2,390,000
-2,340,000
-2,586,000
-2,542,000
-2,548,000
-2,613,000
-2,727,000
-2,630,000
-2,639,000
-2,559,000
-2,480,000
-2,516,000
-2,491,000
-2,528,000
-3,596,000
-3,697,000
-3,435,000
-3,259,000
-3,117,000
-3,295,000
-3,103,000
-3,156,000
-2,899,000
-2,984,000
-3,196,000
-3,443,000
-2,199,000
-2,232,000
-2,252,000
-2,353,000
-2,305,000
-2,454,000
-2,513,000
-2,334,000
-1,925,000
-1,742,000
-1,742,000-1,925,000-2,334,000-2,513,000-2,454,000-2,305,000-2,353,000-2,252,000-2,232,000-2,199,000-3,443,000-3,196,000-2,984,000-2,899,000-3,156,000-3,103,000-3,295,000-3,117,000-3,259,000-3,435,000-3,697,000-3,596,000-2,528,000-2,491,000-2,516,000-2,480,000-2,559,000-2,639,000-2,630,000-2,727,000-2,613,000-2,548,000-2,542,000-2,586,000-2,340,000-2,390,000-2,423,000-2,561,000-2,499,000-2,374,000-2,467,000-2,031,000-913,000-420,000-426,000-442,000-981,000-1,169,000-1,237,000-350,000-164,918-325,493194,180-25,1660000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
3,945,000
4,074,000
3,580,000
3,671,000
3,905,000
3,996,000
4,083,000
4,194,000
4,403,000
12,421,000
13,005,000
13,080,000
13,293,000
13,046,000
13,540,000
13,678,000
13,889,000
14,015,000
14,154,000
14,270,000
14,519,000
14,596,000
14,680,000
14,756,000
14,940,000
15,028,000
15,112,000
15,193,000
15,401,000
16,953,000
17,148,000
17,384,000
17,712,000
17,936,000
18,108,000
18,305,000
18,731,000
18,906,000
19,056,000
19,245,000
19,619,000
19,839,000
0
0
0
0
0
0
0
000000019,839,00019,619,00019,245,00019,056,00018,906,00018,731,00018,305,00018,108,00017,936,00017,712,00017,384,00017,148,00016,953,00015,401,00015,193,00015,112,00015,028,00014,940,00014,756,00014,680,00014,596,00014,519,00014,270,00014,154,00014,015,00013,889,00013,678,00013,540,00013,046,00013,293,00013,080,00013,005,00012,421,0004,403,0004,194,0004,083,0003,996,0003,905,0003,671,0003,580,0004,074,0003,945,000000000000
   Treasury Stock00000-6,533,000-6,525,000-6,528,000-6,524,000-4,594,000-4,590,000-4,591,000-4,585,000-3,143,000-3,020,000-3,022,000-3,017,000-2,264,000-1,972,000-1,958,000-25,110,000-24,504,000-24,501,000-24,505,000-24,502,000-24,108,000-21,849,000-20,845,000-13,331,000-11,923,000-11,419,000-11,427,000-11,430,000-10,852,000-8,760,000-8,383,000-8,918,000-8,839,000-7,314,000-5,816,000-1,314,000-972,000-672,000-673,000-672,000-320,000-119,000-121,000-97,000000000000
   Other Stockholders Equity 
0
0
0
0
12,248,879
11,856,589
11,830,568
15,833,754
0
3,848,000
3,953,000
3,461,000
3,351,000
3,233,000
3,323,000
3,411,000
3,222,000
3,089,000
6,605,000
5,691,000
4,241,000
4,375,000
4,663,000
4,780,000
2,826,000
2,459,000
2,588,000
2,735,000
2,347,000
1,188,000
-6,249,000
-7,169,000
-9,352,000
-9,562,000
-9,477,000
-9,389,000
-9,311,000
-9,709,000
14,995,000
15,176,000
15,120,000
14,695,000
14,914,000
15,088,000
15,162,000
14,146,000
14,315,000
14,466,000
14,651,000
13,095,000
13,311,000
13,496,000
13,647,000
12,827,000
13,041,000
13,312,000
13,132,000
12,671,000
12,671,00013,132,00013,312,00013,041,00012,827,00013,647,00013,496,00013,311,00013,095,00014,651,00014,466,00014,315,00014,146,00015,162,00015,088,00014,914,00014,695,00015,120,00015,176,00014,995,000-9,709,000-9,311,000-9,389,000-9,477,000-9,562,000-9,352,000-7,169,000-6,249,0001,188,0002,347,0002,735,0002,588,0002,459,0002,826,0004,780,0004,663,0004,375,0004,241,0005,691,0006,605,0003,089,0003,222,0003,411,0003,323,0003,233,0003,351,0003,461,0003,953,0003,848,000015,833,75411,830,56811,856,58912,248,8790000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue56,334,000
Cost of Revenue-16,904,000
Gross Profit39,430,00039,430,000
 
Operating Income (+$)
Gross Profit39,430,000
Operating Expense-22,878,000
Operating Income16,625,00016,552,000
 
Operating Expense (+$)
Research Development8,315,000
Selling General Administrative14,752,000
Selling And Marketing Expenses0
Operating Expense22,878,00023,067,000
 
Net Interest Income (+$)
Interest Income648,000
Interest Expense-2,808,000
Other Finance Cost-0
Net Interest Income-2,160,000
 
Pretax Income (+$)
Operating Income16,625,000
Net Interest Income-2,160,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,716,00022,046,000
EBIT - interestExpense = 3,716,000
3,708,000
7,086,000
Interest Expense2,808,000
Earnings Before Interest and Taxes (EBIT)6,524,0006,524,000
Earnings Before Interest and Taxes (EBITDA)14,910,000
 
After tax Income (+$)
Income Before Tax3,716,000
Tax Provision--570,000
Net Income From Continuing Ops4,286,0004,286,000
Net Income4,278,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses47,197,000
Total Other Income/Expenses Net-5,421,0002,160,000
 

Technical Analysis of Abbvie
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abbvie. The general trend of Abbvie is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abbvie's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Abbvie Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AbbVie Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 193.59 < 198.98 < 199.46.

The bearish price targets are: 181.73 > 178.19 > 176.57.

Know someone who trades $ABBV? Share this with them.👇

AbbVie Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AbbVie Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AbbVie Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AbbVie Inc. The current macd is 0.26123889.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abbvie price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Abbvie. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Abbvie price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
AbbVie Inc Daily Moving Average Convergence/Divergence (MACD) ChartAbbVie Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AbbVie Inc. The current adx is 17.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Abbvie shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
AbbVie Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AbbVie Inc. The current sar is 182.65.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AbbVie Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AbbVie Inc. The current rsi is 50.67. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
AbbVie Inc Daily Relative Strength Index (RSI) ChartAbbVie Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AbbVie Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Abbvie price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
AbbVie Inc Daily Stochastic Oscillator ChartAbbVie Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AbbVie Inc. The current cci is 16.63.

AbbVie Inc Daily Commodity Channel Index (CCI) ChartAbbVie Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AbbVie Inc. The current cmo is 1.4996782.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
AbbVie Inc Daily Chande Momentum Oscillator (CMO) ChartAbbVie Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AbbVie Inc. The current willr is -45.67219153.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Abbvie is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AbbVie Inc Daily Williams %R ChartAbbVie Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AbbVie Inc.

AbbVie Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AbbVie Inc. The current atr is 4.13847338.

AbbVie Inc Daily Average True Range (ATR) ChartAbbVie Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AbbVie Inc. The current obv is 232,374,495.

AbbVie Inc Daily On-Balance Volume (OBV) ChartAbbVie Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AbbVie Inc. The current mfi is 41.64.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
AbbVie Inc Daily Money Flow Index (MFI) ChartAbbVie Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AbbVie Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

AbbVie Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AbbVie Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.675
Ma 20Greater thanMa 50187.885
Ma 50Greater thanMa 100187.347
Ma 100Greater thanMa 200192.866
OpenGreater thanClose189.440
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Abbvie with someone you think should read this too:
  • Are you bullish or bearish on Abbvie? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abbvie? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AbbVie Inc

I send you an email if I find something interesting about AbbVie Inc.


Comments

How you think about this?

Leave a comment

Stay informed about AbbVie Inc.

Receive notifications about AbbVie Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.